StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)

Close on Nov 18, 2026Market cap $528.94MP/E –Yield –

Myriad Genetics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Myriad Genetics's operating cash flow for the twelve months ending Jun 30, 2026 was $7.70M. For fiscal 2025 it was $1.80M. Over ten years it grew -37.3% a year on average. The highest annual figure on record is $190.20M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.80M–
FY2024Dec 31, 2024-$8.70M–
FY2023Dec 31, 2023-$110.90M–
FY2022Dec 31, 2022-$106.30M-275.1%
FY2020Jun 30, 2020$60.70M-27.5%
FY2019Jun 30, 2019$83.70M-27.8%
FY2018Jun 30, 2018$115.90M+9.1%
FY2017Jun 30, 2017$106.20M-36.1%
FY2016Jun 30, 2016$166.30M+18.4%
FY2015Jun 30, 2015$140.50M-26.1%
FY2014Jun 30, 2014$190.20M+9.4%
FY2013Jun 30, 2013$173.90M+22.6%
FY2012Jun 30, 2012$141.80M+8.4%
FY2011Jun 30, 2011$130.83M-15.6%
FY2010Jun 30, 2010$155.09M+84.5%
FY2009Jun 30, 2009$84.04M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$8.30M–
Q1 FY2026CQ1 2026Mar 31, 2026-$15.70M–
Q4 FY2025CQ4 2025Dec 31, 2025$10.60M+60.6%
Q3 FY2025CQ3 2025Sep 30, 2025$21.10M+2914.3%
Q2 FY2025CQ2 2025Jun 30, 2025-$13.60M-623.1%
Q1 FY2025CQ1 2025Mar 31, 2025-$16.30M–
Q4 FY2024CQ4 2024Dec 31, 2024$6.60M–
Q3 FY2024CQ3 2024Sep 30, 2024$700.00K–
Q2 FY2024CQ2 2024Jun 30, 2024$2.60M–
Q1 FY2024CQ1 2024Mar 31, 2024-$18.60M–
Q4 FY2023CQ4 2023Dec 31, 2023-$54.70M–
Q3 FY2023CQ3 2023Sep 30, 2023-$22.10M–
Q2 FY2023CQ2 2023Jun 30, 2023-$900.00K–
Q1 FY2023CQ1 2023Mar 31, 2023-$33.20M–
Q4 FY2022CQ4 2022Dec 31, 2022-$7.30M-124.3%
Q3 FY2022CQ3 2022Sep 30, 2022-$2.80M-116.7%
Q2 FY2022CQ2 2022Jun 30, 2022-$49.70M–
Q1 FY2022CQ1 2022Mar 31, 2022-$46.50M-394.3%
Q4 FY2020CQ2 2020Jun 30, 2020$30.00M-4.8%
Q3 FY2020CQ1 2020Mar 31, 2020$16.80M+154.5%
Q2 FY2020CQ4 2019Dec 31, 2019-$1.90M-105.0%
Q1 FY2020CQ3 2019Sep 30, 2019$15.80M+102.6%
Q4 FY2019CQ2 2019Jun 30, 2019$31.50M-34.2%
Q3 FY2019CQ1 2019Mar 31, 2019$6.60M-42.6%
Q2 FY2019CQ4 2018Dec 31, 2018$37.80M+14.5%
Q1 FY2019CQ3 2018Sep 30, 2018$7.80M-66.8%
Q4 FY2018CQ2 2018Jun 30, 2018$47.90M+30.9%
Q3 FY2018CQ1 2018Mar 31, 2018$11.50M-72.0%
Q2 FY2018CQ4 2017Dec 31, 2017$33.00M+5.1%
Q1 FY2018CQ3 2017Sep 30, 2017$23.50M–
Q4 FY2017CQ2 2017Jun 30, 2017$36.60M-4.9%
Q3 FY2017CQ1 2017Mar 31, 2017$41.10M-10.5%
Q2 FY2017CQ4 2016Dec 31, 2016$31.40M-39.7%
Q1 FY2017CQ3 2016Sep 30, 2016-$2.90M-109.7%
Q4 FY2016CQ2 2016Jun 30, 2016$38.50M-24.5%
Q3 FY2016CQ1 2016Mar 31, 2016$45.90M+53.5%
Q2 FY2016CQ4 2015Dec 31, 2015$52.10M–
Q1 FY2016CQ3 2015Sep 30, 2015$29.80M–
Q4 FY2015CQ2 2015Jun 30, 2015$51.00M–
Q3 FY2015CQ1 2015Mar 31, 2015$29.90M–

More Myriad Genetics figures

See a number that looks wrong?